We are live on ! Find out more
CPRX icon

Catalyst Pharmaceutical
CPRX

52 hedge funds and large institutions have $78.7M invested in Catalyst Pharmaceutical in 2014 Q3 according to their latest regulatory filings, with 18 funds opening new positions, 12 increasing their positions, 10 reducing their positions, and 13 closing their positions.

New
Increased
Maintained
Reduced
Closed

135% more call options, than puts

Call options by funds: $1.54M | Put options by funds: $656K

39% more capital invested

Capital invested by funds: $56.4M → $78.7M (+$22.3M)

38% more first-time investments, than exits

New positions opened: 18 | Existing positions closed: 13

20% more repeat investments, than reductions

Existing positions increased: 12 | Existing positions reduced: 10

11% more funds holding

Funds holding: 47 → 52 (+5)

Holders
52
Holders Change
+5
Holders Change %
+10.64%
% of All Funds
1.51%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
18
Increased
12
Reduced
10
Closed
13
Calls
$1.54M
Puts
$656K
Net Calls
+$883K
Net Calls Change
+$816K

Top Buyers

1
BBA
Baker Bros. Advisors
New York
+$11.7M
2
Morgan Stanley
Morgan Stanley
New York
+$3.23M
3
SFM
Sphera Funds Management
Israel
+$1.79M
4
TC
TFS Capital
Pennsylvania
+$599K
5
Renaissance Technologies
Renaissance Technologies
New York
+$514K

Top Sellers

1
O
OrbiMed
New York
-$4.79M
2
PA
Perceptive Advisors
New York
-$3.79M
3
BC
Broadfin Capital
New York
-$2.61M
4
SC
Sophrosyne Capital
New York
-$1.52M
5
GTC
Ghost Tree Capital
New York
-$1.14M
Name Holding Trade Value Shares
Change 		Change in
Stake
Bank of Montreal
51
Bank of Montreal
Ontario, Canada
$5K – – –
Manulife (Manufacturers Life Insurance)
52
Manulife (Manufacturers Life Insurance)
Ontario, Canada
$2 – – –
O
53
OrbiMed
New York
– -$4.79M -1,895,000 Closed
PA
54
Perceptive Advisors
New York
– -$3.79M -1,500,000 Closed
SC
55
Sophrosyne Capital
New York
– -$1.52M -600,000 Closed
GTC
56
Ghost Tree Capital
New York
– -$1.14M -437,296 Closed
Invesco
57
Invesco
Georgia
– -$171K -67,393 Closed
PSC
58
Piper Sandler & Co
Minnesota
– -$127K -50,000 Closed
Group One Trading
59
Group One Trading
Illinois
– -$68.6K -26,248 Closed
GC
60
Guggenheim Capital
Illinois
– -$45K -17,744 Closed
LTFS
61
Ladenburg Thalmann Financial Services
Florida
– -$14K -5,500 Closed
S
62
SignatureFD
Georgia
– -$8K -3,000 Closed
AIG
63
American International Group
New York
– -$5.06K -2,000 Closed
BRWA
64
B. Riley Wealth Advisors
Florida
– -$5.06K -2,000 Closed
SAM
65
Shamrock Asset Management
Texas
– -$1K -200 Closed
1 2
3

CPRX Hedge Fund Activity: Q3 2014 in Review

52 of the 3,446 institutional investors tracked by Wall St. Rank reported a position in Catalyst Pharmaceutical (CPRX) for Q3 2014, worth a combined $78.7M — up 39% from $56.4M a quarter earlier.

Buyers outnumbered sellers: 18 funds opened new CPRX positions and 13 closed out — a net gain of 5 holders — while 12 added to existing stakes and 10 trimmed.

The largest buyer was Baker Bros. Advisors, adding an estimated $11.7M. The largest seller was OrbiMed, exiting entirely with an estimated $4.79M sold.

  • 52 institutional investors held Catalyst Pharmaceutical (CPRX) as of Q3 2014, up from 47 in Q2 2014.
  • Funds reported $78.7M of Catalyst Pharmaceutical stock for Q3 2014, up 39% quarter-over-quarter.
  • 18 funds opened new Catalyst Pharmaceutical positions in Q3 2014 and 13 closed out, a net change of +5 holders.
  • The largest Catalyst Pharmaceutical buyer in Q3 2014 was Baker Bros. Advisors, an estimated $11.7M added.
  • The largest Catalyst Pharmaceutical seller in Q3 2014 was OrbiMed, an estimated $4.79M sold.

Based on aggregated 13F filings for Q3 2014.